Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Averbuch

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Cancer|December 1, 1993
New bisphosphonates in the treatment of bone metastasesS D Averbuch
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Endocrine tumorsS D Averbuch
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
Endocrine tumorsS D Averbuch
Archives of Internal Medicine|February 1, 1980
Fatal pulmonary hemorrhage due to nitrofurantoinS D Averbuch, P Yungbluth
Drugs|December 29, 2000
ZD1839 ('Iressa') as an anticancer agentJ Baselga, S D Averbuch
Annals of Internal Medicine|August 1, 1975
Letter: Acute dystonic reaction due to benzquinamideT E Rose, S D Averbuch
CA: a Cancer Journal for Clinicians|May 1, 1983
Brain metastasis from esophageal carcinomaS D Averbuch, M A Blinder
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
Endocrine tumorsL T Wu, S D Averbuch
Cancer Research|December 1, 1986
Anthracycline photoaffinity labeling of a mitochondrial polypeptide in P388 murine leukemic cell linesS D Averbuch, C J Glover, R L Felsted
Cancer Research|October 5, 2001
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cellsM M Moasser, A Basso, S D Averbuch, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Cancer|December 1, 1993
New bisphosphonates in the treatment of bone metastasesS D Averbuch
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Endocrine tumorsS D Averbuch
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1991
Endocrine tumorsS D Averbuch
Archives of Internal Medicine|February 1, 1980
Fatal pulmonary hemorrhage due to nitrofurantoinS D Averbuch, P Yungbluth
Drugs|December 29, 2000
ZD1839 ('Iressa') as an anticancer agentJ Baselga, S D Averbuch
Annals of Internal Medicine|August 1, 1975
Letter: Acute dystonic reaction due to benzquinamideT E Rose, S D Averbuch
CA: a Cancer Journal for Clinicians|May 1, 1983
Brain metastasis from esophageal carcinomaS D Averbuch, M A Blinder
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1993
Endocrine tumorsL T Wu, S D Averbuch
Cancer Research|December 1, 1986
Anthracycline photoaffinity labeling of a mitochondrial polypeptide in P388 murine leukemic cell linesS D Averbuch, C J Glover, R L Felsted
Cancer Research|October 5, 2001
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cellsM M Moasser, A Basso, S D Averbuch, et al.
Pageof 3